诺华首席执行官万思瀚：加快推进放射配体疗法开发与应用

北京商报03-25

3月24-25日，中国发展高层论坛2024年年会在北京召开。诺华首席执行官万思瀚(Vas Narasimhan)博士出席本次年会。在本届论坛上，诺华提交了主题为“建设有竞争力的创新生态系统，惠及中国患者”的建议，就加快放射配体疗法这一先进疗法的开发与应用积极建言。　　放射配体疗法是新一代创新型靶向治疗放射性药物，通过将放射性同位素与配体结合以直接靶向肿瘤细胞，能够杀伤肿瘤细胞，并最大限度减少对...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422456873?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-25 15:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422456873","market":"hk","top_or_hot":-1,"title":"诺华首席执行官万思瀚：加快推进放射配体疗法开发与应用","media":"北京商报","content":"<div>\n<p>3月24-25日，中国发展高层论坛2024年年会在北京召开。诺华首席执行官万思瀚(Vas Narasimhan)博士出席本次年会。在本届论坛上，诺华提交了主题为“建设有竞争力的创新生态系统，惠及中国患者”的建议，就加快放射配体疗法这一先进疗法的开发与应用积极建言。 　　放射配体疗法是新一代创新型靶向治疗放射性药物，通过将放射性同位素与配体结合以直接靶向肿瘤细胞，能够杀伤肿瘤细胞，并最大限度减少对...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202403253022875294.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺华首席执行官万思瀚：加快推进放射配体疗法开发与应用</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺华首席执行官万思瀚：加快推进放射配体疗法开发与应用\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-25 15:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202403253022875294.html><strong>北京商报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月24-25日，中国发展高层论坛2024年年会在北京召开。诺华首席执行官万思瀚(Vas Narasimhan)博士出席本次年会。在本届论坛上，诺华提交了主题为“建设有竞争力的创新生态系统，惠及中国患者”的建议，就加快放射配体疗法这一先进疗法的开发与应用积极建言。 　　放射配体疗法是新一代创新型靶向治疗放射性药物，通过将放射性同位素与配体结合以直接靶向肿瘤细胞，能够杀伤肿瘤细胞，并最大限度减少对...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202403253022875294.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://finance.eastmoney.com/a/202403253022875294.html","article_id":"2422456873","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403253022875294.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2422456873","pubTimestamp":1711350186,"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"3月24-25日，中国发展高层论坛2024年年会在北京召开。诺华首席执行官万思瀚(VasNarasimhan)博士出席本次年会。在本届论坛上，诺华提交了主题为“建设有竞争力的创新生态系统，惠及中国患者”的建议，就加快放射配体疗法这一先进疗法的开发与应用积极建言。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4532":"文艺复兴科技持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4578":"CAR-T","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","NVS":"诺华","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"Wan Sihan, CEO of Novartis: Accelerate the development and application of radioligand therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1},"content_text":"3月24-25日，中国发展高层论坛2024年年会在北京召开。诺华首席执行官万思瀚(Vas Narasimhan)博士出席本次年会。在本届论坛上，诺华提交了主题为“建设有竞争力的创新生态系统，惠及中国患者”的建议，就加快放射配体疗法这一先进疗法的开发与应用积极建言。 　　放射配体疗法是新一代创新型靶向治疗放射性药物，通过将放射性同位素与配体结合以直接靶向肿瘤细胞，能够杀伤肿瘤细胞，并最大限度减少对健康细胞的损害。放射配体疗法在肿瘤精准靶向治疗方面有着广泛的应用前景。近年来国家陆续发布了多项促进放射性药物开发的政策文件，不断推动我国放射性药物的研发与应用向国际先进水平靠拢。 　　2022年3月，诺华推出的全球首款用于前列腺癌治疗的放射配体疗法获得美国食品药品监督管理局(FDA)批准。目前，中国已经同步启动关于该疗法的国际多中心临床研究。（文章来源：北京商报）","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422456873"}